[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (27)

Search Parameters:
Keywords = uvea

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 1766 KiB  
Review
Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy
by Jonatan Kaszubski, Maciej Gagat, Alina Grzanka, Agata Wawrzyniak, Wiesława Niklińska, Magdalena Łapot and Agnieszka Żuryń
Molecules 2024, 29(22), 5239; https://doi.org/10.3390/molecules29225239 - 6 Nov 2024
Viewed by 895
Abstract
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is [...] Read more.
Melanoma occurs in various forms and body areas, not only in the cutis, but also in mucous membranes and the uvea. Rarer subtypes of that cancer differ in genomic aberrations, which cause their minor sensibility to regular cutaneous melanoma therapies. Therefore, it is essential to discover new strategies for treating rare forms of melanoma. In recent years, interest in applying CDK inhibitors (CDKIs) in cancer therapy has grown, as they are able to arrest the cell cycle and inhibit cell proliferation. Current studies highlight selective CDK4/6 inhibitors, like palbociclib or abemaciclib, as a very promising therapeutic option, since they were accepted by the FDA for advanced breast cancer treatment. However, cells of every subtype of melanoma do not react to CDKIs the same way, which is partly because of the genetic differences between them. Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer. Full article
Show Figures

Figure 1

Figure 1
<p>Regulation of the mammalian cell cycle and the role of the INK4 and CIP/KIP families in inhibiting cyclin–kinase complexes. The cell cycle consists of four main phases (G1, S, G2, M) and a resting phase, G0. The cycle is regulated by cyclin–CDK complexes. During the G1 phase, CDK4/6 binds with cyclin D and phosphorylates the retinoblastoma protein (RB1), leading to the release of E2F from the RB1-E2F complex. E2F then initiates the synthesis of cyclin E, which subsequently binds with CDK2, allowing the cell to enter the S phase. The later phases are regulated by the cyclin A–CDK2, cyclin A–CDK1, and cyclin B–CDK1 complexes. If abnormalities occur during cell cycle progression, the cycle can be halted by two families of CDK inhibitors (CDKIs): the INK4 family (p16, p15, p18, p19), which inhibits the cyclin D–CDK4/6 complex, and the CIP/KIP family (p21, p27, p57), which can inhibit CDK2 from binding to cyclin E or cyclin A, as well as CDK4/6 from binding to cyclin D. (Illustration created with <a href="http://BioRender.com" target="_blank">BioRender.com</a> (accessed on 2 November 2024).</p>
Full article ">Figure 2
<p>Deletion of CDKN2A as well as amplification of CCND1 or CDK4/6 coding genes frequently constitute the reason for an uncontrollable cell proliferation in melanoma. Deletion of CDKN2A (p16 coding gene) prevents the p16 inhibitor from binding with CDK4/6, which leads to uncontrolled progression of the cell. Amplifications of CDK4, CDK6 and cyclin D1 (CCND1) coding genes are also common aberrations that lead to melanoma. (Illustration created with <a href="http://BioRender.com" target="_blank">BioRender.com</a>. URL (accessed on 2 November 2024)).</p>
Full article ">Figure 3
<p>Chemical structures of CDKIs used in rare types of melanoma therapies. (Illustration created with MolView URL (accessed on 2 November 2024)).</p>
Full article ">Figure 4
<p>A summary of preclinical and clinical research connected to the use of CDKIs in treatment of mucosal melanoma (MM), uveal melanoma (UM) and acral melanoma (AM). Several studies pointed out an inhibiting action of selective CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib, dalpiciclib), broad-spectrum pan-CDK inhibitors (P1446A-05, flavopiridol, AT7519), CDK2 inhibitor seliciclib and CDK7/9 inhibitor SNS032 in single or synergistic therapies in various forms of melanoma (MM, UM, AM) treatment. (Illustration created with <a href="http://BioRender.com" target="_blank">BioRender.com</a> URL (accessed on 2 November 2024)).</p>
Full article ">
16 pages, 756 KiB  
Review
Plaque Radiotherapy for Ocular Melanoma
by George Naveen Thomas, I-Ling Chou and Lingam Gopal
Cancers 2024, 16(19), 3386; https://doi.org/10.3390/cancers16193386 - 3 Oct 2024
Viewed by 1008
Abstract
Plaque radiotherapy is an effective treatment modality for medium-sized ocular tumors such as uveal melanoma. The authors review the available literature and concisely summarize the current state of the art of ophthalmic plaque brachytherapy. The choice of radioisotope, which includes Ruthenium-106 and Iodine-125, [...] Read more.
Plaque radiotherapy is an effective treatment modality for medium-sized ocular tumors such as uveal melanoma. The authors review the available literature and concisely summarize the current state of the art of ophthalmic plaque brachytherapy. The choice of radioisotope, which includes Ruthenium-106 and Iodine-125, depends on the intended treatment duration, tumor characteristics, and side effect profiles. Ophthalmic plaques may be customized to allow for the delivery of a precise radiation dose by adjusting seed placement and plaque shape to minimize collateral tissue radiation. High dose rate (HDR) brachytherapy, using beta (e.g., Yttrium-90) and photon-emitting sources (e.g., Ytterbium-169, Selenium-75), allows for rapid radiation dose delivery, which typically lasts minutes, compared to multiple days with low-dose plaque brachytherapy. The efficacy of Ruthenium-106 brachytherapy for uveal melanoma varies widely, with reported local control rates between 59.0% and 98.0%. Factors influencing outcomes include tumor size, thickness, anatomical location, and radiation dose at the tumor apex, with larger and thicker tumors potentially exhibiting poorer response and a higher rate of complications. Plaque brachytherapy is effective for selected tumors, particularly uveal melanoma, providing comparable survival rates to enucleation for medium-sized tumors. The complications of plaque brachytherapy are well described, and many of these are treatable. Full article
(This article belongs to the Special Issue Advances in Brachytherapy in the Treatment of Tumors)
Show Figures

Figure 1

Figure 1
<p>Plaque insertion surgery. (<b>A</b>) Tagging the lateral rectus muscle; (<b>B</b>) disinserting the lateral rectus muscle; (<b>C</b>) passing a traction suture through the stump of the insertion of lateral rectus muscle; (<b>D</b>) passing a scleral suture at the intended location of the anterior eyelet of plaque; (<b>E</b>) placement of the gold plaque with I-125 seeds; (<b>F</b>) anchoring the plaque to the sclera; (<b>G</b>) reattaching the detached lateral rectus; (<b>H</b>) conjunctival closure.</p>
Full article ">
14 pages, 1116 KiB  
Review
Unveiling the Web: Exploring the Multifaceted Role of Neutrophil Extracellular Traps in Ocular Health and Disease
by Salma Adeeb, Tarek Ziad Arabi, Hassan Shah, Sulaiman Alsalameh, Mylia Abu-Shaar, Abduljalil Mohamed El-Sibai, Khaled Alkattan and Ahmed Yaqinuddin
J. Clin. Med. 2024, 13(2), 512; https://doi.org/10.3390/jcm13020512 - 17 Jan 2024
Viewed by 2018
Abstract
Neutrophil extracellular traps (NETs) play an essential role in antimicrobial defense. However, NETs have also been shown to promote and mediate a wide spectrum of diseases, including cancer, diabetes mellitus, cardiovascular diseases, and ocular diseases. Data regarding NETs in ocular diseases remain limited. [...] Read more.
Neutrophil extracellular traps (NETs) play an essential role in antimicrobial defense. However, NETs have also been shown to promote and mediate a wide spectrum of diseases, including cancer, diabetes mellitus, cardiovascular diseases, and ocular diseases. Data regarding NETs in ocular diseases remain limited. In physiological conditions, NETs protect the eye from debris and cleave proinflammatory cytokines, including several interleukins. On the other hand, NETs play a role in corneal diseases, such as dry eye disease and ocular graft-versus-host disease, where they promote acinar atrophy and delayed wound healing. Additionally, NET levels positively correlate with increased severity of uveitis. NETs have also been described in the context of diabetic retinopathy. Although increased NET biomarkers are associated with an increased risk of the disease, NETs also assist in the elimination of pathological blood vessels and the regeneration of normal vessels. Targeting NET pathways for the treatment of ocular diseases has shown promising outcomes; however, more studies are still needed in this regard. In this article, we summarize the literature on the protective roles of NETs in the eye. Then, we describe their pathogenetic effects in ocular diseases, including those of the cornea, uvea, and retinal blood vessels. Finally, we describe the therapeutic implications of targeting NETs in such conditions. Full article
(This article belongs to the Section Ophthalmology)
Show Figures

Figure 1

Figure 1
<p>NET formation is triggered by several external stimuli, which increase intracellular calcium. Subsequently, histone citrullination and chromatin decondensation occur, causing NET release.</p>
Full article ">Figure 2
<p>NETs play several pathological roles in the eye.</p>
Full article ">
18 pages, 13108 KiB  
Article
Quantitative Diffusion-Weighted MR Imaging: Is There a Prognostic Role in Noninvasively Predicting the Histopathologic Type of Uveal Melanomas?
by Pietro Valerio Foti, Corrado Inì, Giuseppe Broggi, Renato Farina, Stefano Palmucci, Corrado Spatola, Maria Chiara Lo Greco, Emanuele David, Rosario Caltabiano, Lidia Puzzo, Andrea Russo, Antonio Longo, Teresio Avitabile and Antonio Basile
Cancers 2023, 15(23), 5627; https://doi.org/10.3390/cancers15235627 - 29 Nov 2023
Cited by 2 | Viewed by 1059
Abstract
Histopathologically, uveal melanomas (UMs) can be classified as spindle cell, mixed cell and epithelioid cell type, with the latter having a more severe prognosis. The aim of our study was to assess the correlation between the apparent diffusion coefficient (ADC) and the histologic [...] Read more.
Histopathologically, uveal melanomas (UMs) can be classified as spindle cell, mixed cell and epithelioid cell type, with the latter having a more severe prognosis. The aim of our study was to assess the correlation between the apparent diffusion coefficient (ADC) and the histologic type of UMs in order to verify the role of diffusion-weighted magnetic resonance imaging (DWI) as a noninvasive prognostic marker. A total of 26 patients with UMs who had undergone MRI and subsequent primary enucleation were retrospectively selected. The ADC of the tumor was compared with the histologic type. The data were compared using both one-way analysis of variance (ANOVA) (assessing the three histologic types separately) and the independent t-test (dichotomizing histologic subtypes as epithelioid versus non-epithelioid). Histologic type was present as follows: the epithelioid cell was n = 4, and the spindle cell was n = 11, the mixed cell type was n = 11. The mean ADC was 1.06 ± 0.24 × 10−3 mm2/s in the epithelioid cells, 0.98 ± 0.19 × 10−3 mm2/s in the spindle cells and 0.96 ± 0.26 × 10−3 mm2/s in the mixed cell type. No significant difference in the mean ADC value of the histopathologic subtypes was found, either when assessing the three histologic types separately (p = 0.76) or after dichotomizing the histologic subtypes as epithelioid and non-epithelioid (p = 0.82). DWI-ADC is not accurate enough to distinguish histologic types of UMs. Full article
Show Figures

Figure 1

Figure 1
<p>Flow diagram displays the patient selection process.</p>
Full article ">Figure 2
<p>Epithelioid cell UM. A 65-year-old female patient with a choroidal melanoma of the right eye. Axial (<b>a</b>) T2-weighted turbo spin-echo and (<b>b</b>) fat-suppressed T1-weighted images show a dome-shaped intraocular lesion along the lateral aspect of the globe (white arrows). Along the posterior aspect of the lesion, a serous retinal detachment is detectable on both T2- and T1-weighted images (white arrowheads). On (<b>c</b>) axial DW image (b = 1000 s/mm<sup>2</sup>) the mass exhibits restricted diffusion with high signal intensity (white arrow), conversely from the retinal detachment that does not show restricted diffusion (white arrowhead). On (<b>d</b>) the axial contrast-enhanced fat-suppressed T1-weighted image, the tumor is enhanced (white arrow); on the other hand, the retinal detachment is not enhanced (white arrowhead). (<b>e</b>) Histological examination: low magnification showing a dome-shaped mass protruding into the posterior segment of the eye and inducing a retinal detachment (H&amp;E, original magnification 25×). (<b>f</b>) High magnification showing the epithelioid cell uveal melanoma composed of nests of polygonal cells with large eosinophilic cytoplasm and rounded nuclei with coarse chromatin (H&amp;E; original magnification 300×).</p>
Full article ">Figure 3
<p>Spindle cell UM. A 39-year-old male patient with a choroidal melanoma of the left eye. Axial (<b>a</b>) T2-weighted turbo spin-echo and (<b>b</b>) fat-suppressed T1-weighted images display a bulky intraocular mass along the posterior aspect of the globe (white arrows). Axial (<b>c</b>) DW image (b = 1000 s/mm<sup>2</sup>) and (<b>d</b>) contrast-enhanced fat-suppressed T1-weighted image. The lesion demonstrates restricted diffusion (white arrow in (<b>c</b>)) and moderate enhancement (white arrow in (<b>d</b>)). Note the hemorrhagic retinal detachment on both sides of the mass are more obvious in the T1-weighted images (white arrowheads in (<b>b</b>,<b>d</b>)). (<b>e</b>) Histological examination: low magnification showing a poorly-pigmented tumor protruding into the posterior segment of the eye (H&amp;E, original magnification 25×). (<b>f</b>) Histological detail (higher magnification) revealing a tumor-induced hemorrhagic retinal detachment (black arrowhead) (H&amp;E, original magnification 100×). (<b>g</b>) Higher magnification showing the tumor with spindle cell morphology consisting of spindle-shaped cells with fusiform nuclei arranged in short intersecting fascicles (H&amp;E; original magnification 300×).</p>
Full article ">Figure 4
<p>Correlation between the ADC value and TP on MRI. Scatterplot (ADC vs. TP) demonstrating that smaller TP tends to have higher ADC values and vice versa (r(24) = −0.87, <span class="html-italic">p</span> &lt; 0.0001). The markers are coded for cell type as follows: <span style="color:red">●</span> epithelioid cell type, <span style="color:#00B050">●</span> mixed cell type and <span style="color:#1F4E79">●</span> spindle cell type.</p>
Full article ">Figure 5
<p>Histological features of UMs. (<b>a</b>) Epithelioid cell UM. Large polygonal cells with large eosinophilic cytoplasm and rounded nuclei with coarse chromatin are seen (H&amp;E, original magnification 300×). (<b>b</b>) Spindle cell UM. Fusiform cells with scant elongated cytoplasm, ovoid nuclei and high nuclear-to-cytoplasmic ratio, arranged in short intersecting fascicles, are seen (H&amp;E, original magnification 300×).</p>
Full article ">
15 pages, 3412 KiB  
Review
Optical Coherence Tomography in Inflammatory and Neoplastic Lesions Deforming the Choroidal Profile
by Elena Bolletta, Luca De Simone, Marco Pellegrini, Chiara Preziosa, Valentina Mastrofilippo, Chantal Adani, Pietro Gentile, Fabrizio Gozzi and Luca Cimino
Diagnostics 2023, 13(12), 1991; https://doi.org/10.3390/diagnostics13121991 - 7 Jun 2023
Cited by 2 | Viewed by 2310
Abstract
The choroid is the main part of the uvea, the vascular layer of the eye that lies between the retina and the sclera. The high vascular component of the choroid makes this structure susceptible to inflammation in multisystemic diseases, as well as the [...] Read more.
The choroid is the main part of the uvea, the vascular layer of the eye that lies between the retina and the sclera. The high vascular component of the choroid makes this structure susceptible to inflammation in multisystemic diseases, as well as the most common site of metastasis in the eye. Therefore, the choroid is involved in many pathological conditions, from uveitis to intraocular tumors. Differentiating between inflammatory and neoplastic lesions deforming the choroidal profile can sometimes be challenging. In addition, scleral disorders can also deform the choroidal profile. Choroidal imaging includes ophthalmic ultrasonography, indocyanine green angiography, and optical coherence tomography (OCT). Recent advances in choroidal imaging techniques, such as enhanced depth imaging optical coherence tomography (EDI-OCT) and swept-source optical coherence tomography (SS-OCT), have facilitated an in-depth analysis of the choroid. The purpose of this review article is to report on and highlight the most common OCT findings to help in the differential diagnosis between inflammatory and neoplastic lesions deforming the choroidal profile. Full article
Show Figures

Figure 1

Figure 1
<p>Multimodal imaging (MMI) of the acute uveitic phase of VKH disease. Ultra-wide field (UWF) pseudocolor fundus image (Optos PLC, Dunfermline, Scotland, UK) with multifocal ERD (<b>A</b>). FA showing peripapillary and posterior pole hyperfluorescence, indicating pooling of the ERD and hyperfluorescence of the optic disc (<b>B</b>,<b>E</b>). Fundus autofluorescence imaging (FAF) highlighting the ERD (<b>D</b>). ICGA hyperfluorescence with leakage from the choroidal vessels and multiple hypofluorescent dots (<b>C</b>,<b>F</b>). EDI-OCT (Spectralis OCT, Heidelberg Engineering, Heidelberg, Germany) showing multifocal ERD (<b>G</b>), RPE undulation (<b>H</b>), and diffuse thickening of the choroid, which all reduce post-treatment (<b>I</b>,<b>J</b>).</p>
Full article ">Figure 2
<p>MMI of the chronic recurrent uveitic phase of VKH disease. UWF fundus image (<b>A</b>). FA (<b>B</b>,<b>C</b>). FAF (<b>D</b>). ICGA with multiple coalescent hypofluorescent dots (<b>E</b>,<b>F</b>). EDI-OCT showing corresponding localized thickening of the choroid, which assumes a convex appearance with consequent bulging of the outer retina (‘choroidal bulging’), indicated by the asterisk (<b>G</b>) and reduction post-treatment (<b>H</b>).</p>
Full article ">Figure 3
<p>MMI of choroidal tuberculoma. UWF fundus image and FAF showing a solitary, active round-shaped yellowish subretinal lesion nasally to the optic disc (asterisk) and healed lesion along the inferotemporal vascular arcade (arrow) (<b>A</b>,<b>D</b>). FA of the active tuberculoma shows an early hypofluorescence with late hyperfluorescence, while inactive healed tuberculomas show transmission hyperfluorescence (<b>B</b>,<b>C</b>). ICGA shows oval hypofluorescent lesions, both in the early and late phases of the exam (<b>E</b>,<b>F</b>). EDI-OCT active choroidal tuberculoma appears as a hyporeflective lesion involving the choroidal stroma and exhibits increased signal transmission with localized overlying hyperreflective material, indicative of an inflammatory infiltrate, as indicated by the asterisk (<b>G</b>); healed choroidal tuberculoma shows alteration of outer retinal layers with increased transmission due to atrophy of the RPE, as indicated by the arrow (<b>H</b>).</p>
Full article ">Figure 4
<p>MMI of idiopathic nodular posterior scleritis. UWF fundus image and FAF of amelanotic subretinal mass without lipofuscin or drusen along the inferotemporal vascular arcade and chorioretinal folds (<b>A</b>,<b>B</b>). B-scan US shows sessile unilobed lesion with high reflectivity and oedema in sub-Tenon’s space (‘T’ sign) (<b>C</b>). EDI-OCT shows elevated profile of the retina due to the presence of scleral mass with a normal choroid tissue beneath and focal ERD (<b>D</b>,<b>E</b>).</p>
Full article ">Figure 5
<p>MMI of choroidal melanoma. UWF fundus image of a pigmented lesion with clumped orange pigment (lipofuscin) (<b>A</b>). FAF shows a patchy pattern with hyperautofluorescence in the areas of lipofuscin deposit (<b>B</b>). US B-scan shows a dome-shaped mass (<b>C</b>) with low-to-medium homogeneous internal reflectivity on A-scan (<b>D</b>). SS-OCT (<b>E</b>) and EDI-OCT (<b>F</b>) display dome-shaped choroidal lesion with compression of the choriocapillaris, overlying shaggy photoreceptors, lipofuscin deposition as hyperreflective clumps atop the RPE, and perilesional subretinal fluid.</p>
Full article ">Figure 6
<p>MMI of choroidal metastasis. UWF fundus imaging with creamy white lesion in the posterior pole (<b>A</b>). FAF with hypo- and hyperautofluorescence (<b>D</b>). FA with hypofluorescence in the early phase (<b>B</b>) and pinpoints and leakage areas on the mass in the late phase (<b>C</b>). ICGA hypofluorescence in early and late phases (<b>E</b>,<b>F</b>). EDI-OCT showing “lumpy, bumpy” appearance associated with overlying subretinal fluid (<b>G</b>). US flat multilobular mass with medium-to-high internal reflectivity (<b>H</b>).</p>
Full article ">Figure 7
<p>MMI of choroidal hemangioma. UWF fundus image and FAF of choroidal hemangioma in the posterior pole (<b>A</b>,<b>D</b>). FA showing mild lacy hyperfluorescence (<b>B</b>,<b>C</b>). ICGA shows early intense hyperfluorescence with washout effect in the late phase (<b>E</b>,<b>F</b>). EDI-OCT (<b>G</b>) and SS-OCT (Optos PLC, Dunfermline, Scotland, UK) (<b>H</b>) showing focal thickening of the choroid without compression of the choriocapillaris. US dome-shaped acoustically solid mass similar to the surrounding normal choroid (<b>I</b>) with high internal reflectivity (<b>J</b>).</p>
Full article ">Figure 8
<p>MMI of choroidal lymphoma. UWF fundus image of a patient with choroidal lymphoma and exudative retinal detachment (<b>A</b>). FAF (<b>D</b>) and FA (<b>B</b>,<b>C</b>), respectively, show areas of hypoautofluorescence with hyperautofluorescent spots (<b>D</b>) and areas of hyperfluorescence with mottled hypofluorescence (<b>B</b>,<b>C</b>) due to atrophic-pigmentary remodeling of the RPE. ICGA reveals hypofluorescent round areas (<b>E</b>,<b>F</b>). SS-OCT showing a rippled surface choroidal contour with infiltration and thickening of the choroid, inward compression of the choriocapillaris, and overlying subretinal fluid (<b>G</b>,<b>H</b>).</p>
Full article ">
18 pages, 2212 KiB  
Review
Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank
by Arnaud Martel, Lauris Gastaud, Christelle Bonnetaud, Sacha Nahon-Esteve, Kevin Washetine, Olivier Bordone, Myriam Salah, Virginie Tanga, Julien Fayada, Virginie Lespinet, Maryline Allegra, Salome Lalvee, Katia Zahaf, Stephanie Baillif, Corine Bertolotto, Baharia Mograbi, Sandra Lassalle and Paul Hofman
Cancers 2023, 15(8), 2372; https://doi.org/10.3390/cancers15082372 - 19 Apr 2023
Cited by 3 | Viewed by 1656
Abstract
Ophthalmic malignancies include various rare neoplasms involving the conjunctiva, the uvea, or the periocular area. These tumors are characterized by their scarcity as well as their histological, and sometimes genetic, diversity. Uveal melanoma (UM) is the most common primary intraocular malignancy. UM raises [...] Read more.
Ophthalmic malignancies include various rare neoplasms involving the conjunctiva, the uvea, or the periocular area. These tumors are characterized by their scarcity as well as their histological, and sometimes genetic, diversity. Uveal melanoma (UM) is the most common primary intraocular malignancy. UM raises three main challenges highlighting the specificity of ophthalmic malignancies. First, UM is a very rare malignancy with an estimated incidence of 6 cases per million inhabitants. Second, tissue biopsy is not routinely recommended due to the risk of extraocular dissemination. Third, UM is an aggressive cancer because it is estimated that about 50% of patients will experience metastatic spread without any curative treatment available at this stage. These challenges better explain the two main objectives in the creation of a dedicated UM biobank. First, collecting UM samples is essential due to tissue scarcity. Second, large-scale translational research programs based on stored human samples will help to better determine UM pathogenesis with the aim of identifying new biomarkers, allowing for early diagnosis and new targeted treatment modalities. Other periocular malignancies, such as conjunctival melanomas or orbital malignancies, also raise specific concerns. In this context, the number of biobanks worldwide dedicated to ocular malignancies is very limited. The aims of this article were (i) to describe the specific challenges raised by a dedicated ocular malignancy biobank, (ii) to report our experience in setting up such a biobank, and (iii) to discuss future perspectives in this field. Full article
(This article belongs to the Special Issue Metastatic Melanoma: From Gene Profiling to Targeted Therapy)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>The spectacular variety of periocular melanomas.</p>
Full article ">Figure 2
<p>Whole biobanking process for UM patients.</p>
Full article ">Figure 3
<p>Composition of the NOMA Biobank samples.</p>
Full article ">Figure 4
<p>Summary of the UM tissue and liquid biopsy samples available in the NOMA Biobank.</p>
Full article ">Figure 5
<p>Details of the origin of UM samples included in the NOMA Biobank. Primary enucleation: no treatment before surgery. Secondary enucleation: treatment before surgery (proton therapy).</p>
Full article ">Figure 6
<p>Pathological TNM classification of the tumors of enucleated patients.</p>
Full article ">Figure 7
<p>Chromosomal abnormalities and Trolet classification of 28 enucleated UM patients.</p>
Full article ">Figure 8
<p>Number of scientific publications related to ocular oncology and translational research published over the last 4 years by Nice University Hospital thanks to the use of samples.</p>
Full article ">
14 pages, 4736 KiB  
Article
Morphological and Morphometric Analysis of Canine Choroidal Layers Using Spectral Domain Optical Coherence Tomography
by Jowita Zwolska, Ireneusz Balicki and Agnieszka Balicka
Int. J. Environ. Res. Public Health 2023, 20(4), 3121; https://doi.org/10.3390/ijerph20043121 - 10 Feb 2023
Cited by 2 | Viewed by 1829
Abstract
The choroid, a multifunctional tissue, has been the focus of research interest for many scientists. Its morphology and morphometry facilitate an understanding of pathological processes within both the choroid and retina. This study aimed to determine the choroidal layer thicknesses in healthy, mixed-breed [...] Read more.
The choroid, a multifunctional tissue, has been the focus of research interest for many scientists. Its morphology and morphometry facilitate an understanding of pathological processes within both the choroid and retina. This study aimed to determine the choroidal layer thicknesses in healthy, mixed-breed mesocephalic dogs, both male (M) and female (F), using spectral domain optical coherence tomography (SD-OCT) with radial, cross-sectional, and linear scans. The dogs were divided into two groups based on age: middle-aged (MA) and senior (SN). Thicknesses of choroidal layers, namely RPE–Bruch’s membrane–choriocapillaris complex (RPE-BmCc) with tapetum lucidum in the tapetal fundus, the medium-sized vessel layer (MSVL), and the large vessel layer with lamina suprachoroidea (LVLS), as well as whole choroidal thickness (WCT), were measured manually using the caliper function integrated into the OCT software. Measurement was performed dorsally and ventrally at a distance of 5000–6000 μm temporally and nasally at a distance of 4000–7000 μm to the optic disc on enhanced depth scans. The measurements were conducted temporally and nasally in both the tapetal (temporal tapetal: TempT, nasal tapetal: NasT) and nontapetal (temporal nontapetal: TempNT, nasal nontapetal: NasNT) fundus. The ratio of the MSVL thickness to the LVLS thickness for each region was calculated. In all examined dogs, the RPE-BmCc in the dorsal (D) region and MSVL in the Tt region were significantly thicker than those in the other regions. The MSVL was thinner in the ventral (V) region than in the D, TempT, TempNT and NasT regions. The MSVL was significantly thinner in the NasNT region than in the D region. LVLS thickness and WCT were significantly greater in the D and TempT regions than those in the other regions and significantly lesser in the V region than those in the other regions. The MSVL-to-LVLS thickness ratio did not differ between the age groups. Our results reveal that the choroidal thickness profile does not depend on age. Our findings can be used to document the emergence and development of various choroidal diseases in dogs in the future. Full article
Show Figures

Figure 1

Figure 1
<p>Spectral-domain optical coherence tomography (SD-OCT) scan with the choroidal layer measurements in the tapetal (<bold>a</bold>) and nontapetal (<bold>b</bold>) fundus: (A) RPE–Bruch’s membrane–choriocapillaris complex (RPE-BmCc) with tapetum lucidum, (B) medium-sized vessel layer (MSVL), and (C) large vessel layer with lamina suprachoroidea (LVLS).</p>
Full article ">Figure 2
<p>SD-OCT scan taken in the dorsal tapetal fundus. The black arrow indicates choriocapillaris (hyporeflective line). The choriocapillaris is located between the RPE–Bruch’s membrane complex and the tapetum lucidum.</p>
Full article ">Figure 3
<p>Measurements of choroidal thickness in the ventral region on SD-OCT scan (green arrow in the fundus photograph). Three measurements were conducted for each analyzed segment: the first one in the center of the scan and the other two on the right and left at a distance of 1500 µm from the center. The measurements were performed at a distance of 5000–6000 µm to the optic disc (white arrows in the fundus photograph).</p>
Full article ">Figure 4
<p>Measurements of choroidal layer thickness in the nasal nontapetal region on SD-OCT scan (green arrow in the fundus photograph). Measurements on linear scans were performed at distances of 4000–7000 µm. Measurements in the temporal and nasal nontapetal regions were taken at a distance of 500–2000 µm ventrally from the border between the tapetal and nontapetal regions (white arrows in the fundus photograph).</p>
Full article ">
32 pages, 1809 KiB  
Review
Oxidative Stress in the Anterior Ocular Diseases: Diagnostic and Treatment
by Azza Dammak, Cristina Pastrana, Alba Martin-Gil, Carlos Carpena-Torres, Assumpta Peral Cerda, Mirjam Simovart, Pilar Alarma, Fernando Huete-Toral and Gonzalo Carracedo
Biomedicines 2023, 11(2), 292; https://doi.org/10.3390/biomedicines11020292 - 20 Jan 2023
Cited by 30 | Viewed by 5913
Abstract
The eye is a metabolically active structure, constantly exposed to solar radiations making its structure vulnerable to the high burden of reactive oxygen species (ROS), presenting many molecular interactions. The biomolecular cascade modification is caused especially in diseases of the ocular surface, cornea, [...] Read more.
The eye is a metabolically active structure, constantly exposed to solar radiations making its structure vulnerable to the high burden of reactive oxygen species (ROS), presenting many molecular interactions. The biomolecular cascade modification is caused especially in diseases of the ocular surface, cornea, conjunctiva, uvea, and lens. In fact, the injury in the anterior segment of the eye takes its origin from the perturbation of the pro-oxidant/antioxidant balance and leads to increased oxidative damage, especially when the first line of antioxidant defence weakens with age. Furthermore, oxidative stress is related to mitochondrial dysfunction, DNA damage, lipid peroxidation, protein modification, apoptosis, and inflammation, which are involved in anterior ocular disease progression such as dry eye, keratoconus, uveitis, and cataract. The different pathologies are interconnected through various mechanisms such as inflammation, oxidative stress making the diagnostics more relevant in early stages. The end point of the molecular pathway is the release of different antioxidant biomarkers offering the potential of predictive diagnostics of the pathology. In this review, we have analysed the oxidative stress and inflammatory processes in the front of the eye to provide a better understanding of the pathomechanism, the importance of biomarkers for the diagnosis of eye diseases, and the recent treatment of anterior ocular diseases. Full article
Show Figures

Figure 1

Figure 1
<p>Scheme of oxidative stress role in anterior ocular diseases. UVA: Ultraviolet A, ROS: Reactive Oxygen Species, IOP: intraocular pressure, ECM: Extracellular Matrix.</p>
Full article ">
23 pages, 723 KiB  
Review
The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review
by Yasmine Yousra Sadok Cherif, Chakib Djeffal, Hashem Abu Serhan, Ahmed Elnahhas, Hebatallah Yousef, Basant E. Katamesh, Basel Abdelazeem and Abdelaziz Abdelaal
Vaccines 2023, 11(1), 69; https://doi.org/10.3390/vaccines11010069 - 28 Dec 2022
Cited by 13 | Viewed by 4095
Abstract
Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized [...] Read more.
Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events. Full article
(This article belongs to the Special Issue Ophthalmic Adverse Events following SARS-CoV-2 Vaccination)
Show Figures

Figure 1

Figure 1
<p>A PRISMA flow diagram showing the database search and screening results.</p>
Full article ">
26 pages, 1402 KiB  
Review
Therapeutic Potential of Honey and Propolis on Ocular Disease
by Norhashima Abd Rashid, Siti Nur Farhana Mohammed, Syarifah Aisyah Syed Abd Halim, Norzana Abd Ghafar and Nahdia Afiifah Abdul Jalil
Pharmaceuticals 2022, 15(11), 1419; https://doi.org/10.3390/ph15111419 - 17 Nov 2022
Cited by 16 | Viewed by 5441
Abstract
Honey and propolis have recently become the key target of attention for treating certain diseases and promoting overall health and well-being. A high content of flavonoids and phenolic acids found in both honey and propolis contributes to the antioxidant properties to scavenge free [...] Read more.
Honey and propolis have recently become the key target of attention for treating certain diseases and promoting overall health and well-being. A high content of flavonoids and phenolic acids found in both honey and propolis contributes to the antioxidant properties to scavenge free radicals. Honey and propolis also exhibited antibacterial effects where they act in two ways, namely the production of hydrogen peroxide (H2O2) and gluconic acids following the enzymatic activities of glucose oxidase, which exerts oxidative damage on the bacteria. Additionally, the anti-inflammatory effects of honey and propolis are mainly by reducing proinflammatory factors such as interleukins and tumor necrosis factor alpha (TNF-α). Their effects on pain were discovered through modulation at a peripheral nociceptive neuron or binding to an opioid receptor in the higher center. The aforementioned properties of honey have been reported to possess potential therapeutic topical application on the exterior parts of the eyes, particularly in treating conjunctivitis, keratitis, blepharitis, and corneal injury. In contrast, most of the medicinal values of propolis are beneficial in the internal ocular area, such as the retina, optic nerve, and uvea. This review aims to update the current discoveries of honey and propolis in treating various ocular diseases, including their antioxidant, anti-inflammatory, antibacterial, and anti-nociceptive properties. In conclusion, research has shown that propolis and honey have considerable therapeutic promise for treating various eye illnesses, although the present study designs are primarily animal and in vitro studies. Therefore, there is an urgent need to translate this finding into a clinical setting. Full article
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Flavonoids compound in honey and propolis.</p>
Full article ">Figure 2
<p>Phenolic acids in honey and propolis.</p>
Full article ">Figure 3
<p>Medicinal values of honey in treating ocular disease.</p>
Full article ">Figure 4
<p>Medicinal values of propolis in treating ocular disease.</p>
Full article ">
12 pages, 491 KiB  
Article
Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature
by Dongchen Li, Li Yang, Feng Bai, Shun Zeng and Xiaoli Liu
Brain Sci. 2022, 12(9), 1168; https://doi.org/10.3390/brainsci12091168 - 31 Aug 2022
Cited by 2 | Viewed by 1887
Abstract
There are increasing reports that anticancer drugs, especially immunotherapy and specific targeted therapy, can cause uveitis, but it is not fully understood whether the clinical features of this drug-induced uveitis differ from those of other types of uveitis and whether there are differences [...] Read more.
There are increasing reports that anticancer drugs, especially immunotherapy and specific targeted therapy, can cause uveitis, but it is not fully understood whether the clinical features of this drug-induced uveitis differ from those of other types of uveitis and whether there are differences between these drugs. We retrospectively reviewed the published cases and case series in PubMed, Embase, Web of Science, and Cochrane from January 2011 to October 2020. We analysed the data, including patients’ basic information, medications used, duration of use, time to onset, clinical manifestations, diagnosis, treatment, and prognosis of uveitis. We focused on the differences in uveitis caused by immunotherapy and specific targeted therapy. Altogether 93 cases (43 men, 48 women, and 2 cases whose gender was not mentioned) reported in 55 articles were included in this study. The average age was 59.6 ± 13.5 years. Eighty percent of the patients had bilateral involvement. Sixty cases were caused by immunotherapy (64.5%), and twenty-six were caused by specific targeted therapy (27.9%). No significant difference was found in the mean time from treatment to onset between the two groups. Anticancer drug-induced uveitis can involve all parts of the uvea from anterior to posterior, manifested as anterior chamber flare, anterior chamber cells, papillitis, macular oedema, subretinal fluid, and choroidal effusion. Anterior uveitis (24 cases, 40.0%) was more common in immunotherapy, and intermediate uveitis (8 cases, 30.8%) was more common in specific targeted therapy. The mean LogMAR visual acuity in specific targeted therapy at presentation was lower than in immunotherapy, but it was not statistically significant. Corticosteroid therapy can effectively control uveitis induced by anticancer drugs. However, the survival prognosis was poor. Among the 19 patients with reported cancer prognosis, seven (36.8%) had no cancer progression, eight (42.1%) had further metastases, and four (21.0%) died of cancer. In conclusion, uveitis caused by anticancer drugs involves both eyes and manifests as various types of uveitis. Patients with specific targeted therapy are more likely to have intermediate uveitis and low vision, and immunotherapy patients are more likely to have anterior uveitis. Corticosteroids are effective against uveitis caused by anticancer drugs. Full article
(This article belongs to the Special Issue Dissecting Neuroinflammation and Ocular System)
Show Figures

Figure 1

Figure 1
<p>The flowchart for identification of articles in databases.</p>
Full article ">
9 pages, 474 KiB  
Article
Conjunctival Swab Findings in 484 COVID-19 Patients in Four Hospital Centers in Slovakia
by Alena Furdova, Pavol Vesely, Michal Trnka, Elena Novakova, Michal Stubna, Robert Furda, Lubica Branikova and Zuzana Pridavkova
Vision 2022, 6(3), 46; https://doi.org/10.3390/vision6030046 - 22 Jul 2022
Cited by 2 | Viewed by 2069
Abstract
Since 2020, the COVID-19 (Coronavirus Disease 2019) has quickly become a worldwide health problem. Ophthalmologists must deal with symptoms as well. For the positive detection in the conjunctival sac swab in COVID-19 patients hospitalized in Slovakia during March 2021 in four hospital centers, [...] Read more.
Since 2020, the COVID-19 (Coronavirus Disease 2019) has quickly become a worldwide health problem. Ophthalmologists must deal with symptoms as well. For the positive detection in the conjunctival sac swab in COVID-19 patients hospitalized in Slovakia during March 2021 in four hospital centers, we used a test based on a polymerase chain reaction (PCR). In a group of 484 patients, 264 males (55%) and 220 females (45%) with clinical symptoms were identified with COVID-19 as a clinical diagnosis. The PCR test swab results from the conjunctival sac taken on the same day were positive in 58 patients (12%), 31 males (with a mean age of 74.6 ± 13.59 years) and 27 females (with a mean age of 70.63 ± 14.17 years); negative in 417 patients (86%); and 9 patients (2%) had an unclear result. The cycle threshold values comparing the nasopharynx and conjunctiva were also different in the group of all patients divided by age and gender. In COVID-19 patients the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was detectable using PCR test in the nasopharynx but also in the conjunctival sac swab, where the positivity rate was only 12%. Full article
Show Figures

Figure 1

Figure 1
<p>Patients in the group with COVID-19-positive PCR test and patients with positive result from the conjunctival sac divided by age and gender.</p>
Full article ">
14 pages, 919 KiB  
Review
Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives
by Alessandra Loda, Marta Turati, Francesco Semeraro, Sara Rezzola and Roberto Ronca
Int. J. Mol. Sci. 2022, 23(7), 3835; https://doi.org/10.3390/ijms23073835 - 30 Mar 2022
Cited by 10 | Viewed by 3435
Abstract
Ocular tumors are a family of rare neoplasms that develop in the eye. Depending on the type of cancer, they mainly originate from cells localized within the retina, the uvea, or the vitreous. Even though current treatments (e.g., radiotherapy, transpupillary thermotherapy, cryotherapy, chemotherapy, [...] Read more.
Ocular tumors are a family of rare neoplasms that develop in the eye. Depending on the type of cancer, they mainly originate from cells localized within the retina, the uvea, or the vitreous. Even though current treatments (e.g., radiotherapy, transpupillary thermotherapy, cryotherapy, chemotherapy, local resection, or enucleation) achieve the control of the local tumor in the majority of treated cases, a significant percentage of patients develop metastatic disease. In recent years, new targeting therapies and immuno-therapeutic approaches have been evaluated. Nevertheless, the search for novel targets and players is eagerly required to prevent and control tumor growth and metastasis dissemination. The fibroblast growth factor (FGF)/FGF receptor (FGFR) system consists of a family of proteins involved in a variety of physiological and pathological processes, including cancer. Indeed, tumor and stroma activation of the FGF/FGFR system plays a relevant role in tumor growth, invasion, and resistance, as well as in angiogenesis and dissemination. To date, scattered pieces of literature report that FGFs and FGFRs are expressed by a significant subset of primary eye cancers, where they play relevant and pleiotropic roles. In this review, we provide an up-to-date description of the relevant roles played by the FGF/FGFR system in ocular tumors and speculate on its possible prognostic and therapeutic exploitation. Full article
(This article belongs to the Special Issue Tumor Microenvironment from a Precision Medicine Perspective 2.0)
Show Figures

Figure 1

Figure 1
<p>Tumors of the eye. Ophthalmic tumors affect specific ocular structures. Retinoblastoma (green) arises in the retina; conjunctival melanoma (blue) involves the conjunctival epithelium; uveal melanoma (purple) develops from any region of the uveal tract; ocular lymphomas (grey) derive from the vitreoretinal tissue or from the uvea.</p>
Full article ">Figure 2
<p>Fibroblast Growth Factor (FGF)/FGF receptor (FGFR) signaling pathways. The formation of two FGF-FGFR- heparan sulfate proteoglycan (HSPG) ternary complexes induces receptor dimerization and trans-phosphorylation of the tyrosine kinase (TK) domains. This event leads to the docking of intracellular receptor substrates and consequent activation of downstream signaling pathways. Deregulation of FGF/FGFR-mediated cell activities promotes tumor onset and progression.</p>
Full article ">Figure 3
<p>Overexpression of FGFs and FGFRs in human primary uveal melanoma. Analysis of The Cancer Genome Atlas (TCGA) dataset performed on 80 primary human uveal melanoma specimens. (<b>A</b>) Pie charts showing the percentage of samples with mRNA overexpression of <span class="html-italic">FGFs</span> (left panel) or <span class="html-italic">FGFRs</span> (right panel). (<b>B</b>) Percentage of uveal melanoma patients with mRNA overexpression of different members of the FGF (upper panel) or FGFR (lower panel) families. (<b>C</b>) Probability of overall survival of patients with or without FGF (upper panel) or FGFR (lower panel) alterations. Statistical analysis: Logrank Test.</p>
Full article ">
23 pages, 1502 KiB  
Review
SWI/SNF Chromatin Remodeling Enzymes in Melanoma
by Megan R. Dreier and Ivana L. de la Serna
Epigenomes 2022, 6(1), 10; https://doi.org/10.3390/epigenomes6010010 - 18 Mar 2022
Cited by 10 | Viewed by 7200
Abstract
Melanoma is an aggressive malignancy that arises from the transformation of melanocytes on the skin, mucosal membranes, and uvea of the eye. SWI/SNF chromatin remodeling enzymes are multi-subunit complexes that play important roles in the development of the melanocyte lineage and in the [...] Read more.
Melanoma is an aggressive malignancy that arises from the transformation of melanocytes on the skin, mucosal membranes, and uvea of the eye. SWI/SNF chromatin remodeling enzymes are multi-subunit complexes that play important roles in the development of the melanocyte lineage and in the response to ultraviolet radiation, a key environmental risk factor for developing cutaneous melanoma. Exome sequencing has revealed frequent loss of function mutations in genes encoding SWI/SNF subunits in melanoma. However, some SWI/SNF subunits have also been demonstrated to have pro-tumorigenic roles in melanoma and to affect sensitivity to therapeutics. This review summarizes studies that have implicated SWI/SNF components in melanomagenesis and have evaluated how SWI/SNF subunits modulate the response to current therapeutics. Full article
(This article belongs to the Collection Epigenetics of Melanoma)
Show Figures

Figure 1

Figure 1
<p>SWI/SNF chromatin remodeling complexes. All three complexes have a central ATPase, various common and unique subunits. (<b>A</b>). Canonical cBAF contains ARID1A or ARID1B and DPF1, 2, or 3 as signature subunits. The ATPase can be either SMARCA4 or SMARCA2. (<b>B</b>) PBAF complexes contain ARID2, PBRM1, BRD7, and PHF10 as signature subunits and SMARCA4 as the ATPase. (<b>C</b>) Noncanonical ncBAF contains BRD9 and BICRA/BICRAL as signature subunits and SMARCA4 as the ATPase.</p>
Full article ">Figure 2
<p>SWI/SNF subunit alterations in cutaneous melanoma. Graphic depiction of TCGA Pan Cancer Atlas datasets for cutaneous melanoma analyzed using the cBioportal tool [<a href="#B71-epigenomes-06-00010" class="html-bibr">71</a>,<a href="#B72-epigenomes-06-00010" class="html-bibr">72</a>] as in <a href="#epigenomes-06-00010-t001" class="html-table">Table 1</a>.</p>
Full article ">Figure 3
<p>Comparison of the frequency of SWI/SNF genetic alterations in melanoma with other cancers. The graphs show seven subunits that are most frequently altered in melanoma in relation to the seven cancer types (out of 32), displaying the most frequent alterations in the respective genes. The dataset is from TCGA and evaluated with the cBioportal tool [<a href="#B71-epigenomes-06-00010" class="html-bibr">71</a>,<a href="#B72-epigenomes-06-00010" class="html-bibr">72</a>]. Stars highlight melanoma data.</p>
Full article ">
16 pages, 3448 KiB  
Article
Bleb-Independent Glaucoma Surgery to Activate the Uveolymphatic Route of Non-Trabecular Aqueous Humor Outflow: Short-Term Clinical and OCT Results
by Vinod Kumar, Kamal Abdulmuhsen Abu Zaalan, Andrey Igorevich Bezzabotnov, Galina Nikolaevna Dushina, Ahmad Saleh Soliman Shradqa, Zarina Shaykuliyevna Rustamova and Mikhail Aleksandrovich Frolov
Vision 2022, 6(1), 4; https://doi.org/10.3390/vision6010004 - 12 Jan 2022
Cited by 2 | Viewed by 3353
Abstract
The deep sclerectomy technique was modified to enhance aqueous humor (AH) outflow via the non-trabecular pathway. A pilot study was carried out to assess its safety and effectiveness. Thirty-eight patients were under observation. After superficial scleral flap (4 × 4 mm), deep scleral [...] Read more.
The deep sclerectomy technique was modified to enhance aqueous humor (AH) outflow via the non-trabecular pathway. A pilot study was carried out to assess its safety and effectiveness. Thirty-eight patients were under observation. After superficial scleral flap (4 × 4 mm), deep scleral layers were divided into three parts by three parallel-to-limbus incisions. Deep sclerectomy without creating a window in the Descemetes’ membrane was carried out in the distal part. A collagen implant was placed under the sclera of the remaining two parts with one end in the intrascleral pool. The third proximal part was excised to expose the uvea and implant. A Nd:YAG laser trabeculotomy at the surgery site was made on postoperative days 7–10. Outcome measures were IOP change, use of hypotensive medication(s), complications, and the need for a second surgery. At six months, the mean IOP decreased from 29.1 ± 9.2 mm Hg to 14.0 ± 4.3 mm Hg (p = 1.4 × 10−9); hypotensive medication use reduced from 2.9 ± 0.9 to 0.6 ± 1.0 (p = 1.3 × 10−10); complete success was achieved in 68.4% of cases and partial success was achieved in 31.6% of cases. Intraoperative and postoperative complications were rare and manageable. The OCT of the surgery site revealed the absence of bleb in all cases. Lymphatic vessels with characteristic bicuspid valves in their lumen were detected in conjunctiva near the operation site and over it in 32 patients. IOP decrease in the proposed technique was achieved by activation of the uveolymphatic route of AH outflow. Full article
Show Figures

Figure 1

Figure 1
<p>Surgical steps. (<b>a</b>) After fornix-based conjunctival peritomy, a 4 × 4 mm ½ limbal-based superficial scleral flap was fashioned. (<b>b</b>) Parallel to the limbus, and 2, 3 and 4 mm away from it, three transversal incisions up to the uveal tissue were made in the deep scleral layers to divide them into three parts. (<b>c</b>–<b>e</b>) In the distal part, a modified deep sclerectomy was performed without creation of a window in Descemete’s membrane. (<b>f</b>) A part of the juxtacanalicular connective tissue was stripped off from the inner wall of the Schlemm’s canal and removed. (<b>g</b>) Under the middle and proximal parts of the sclera, the uvea was detached with a thin blunt spatula. (<b>h</b>,<b>i</b>) A strip of collagen implant was inserted into the suprauveal space with forceps. Its anterior end lay in the intrascleral pool to act as a space maintainer. (<b>j</b>,<b>k</b>) The proximal scleral part was excised, exposing the implant and uvea. (<b>l</b>) The superficial scleral flap was replaced and fixed by two 10–0 nylon interrupted sutures placed in each corner.</p>
Full article ">Figure 2
<p>Schematic presentation of OCT evaluation of the surgery site and adjacent areas in the superior hemisphere of the eye globe. At each site, five horizontal and five vertical Raster scans were obtained.</p>
Full article ">Figure 3
<p>OCT evaluation of surgery and adjunct sites. (<b>A</b>) OCT scan of surgery site, showing intrascleral reservoir with collagen implant (CI), covered by superficial scleral flap (SSF) and conjunctiva (CO). No filtration bleb cavity or subepithelial microcysts are seen over the implant and in the nearby area. A lymphatic vessel (LV) with bicuspid lymphatic valves (BLV) in its lumen (white arrows) is seen running horizontally over the surgery site. (<b>B</b>) OCT scan of conjunctiva adjacent to surgery site showing a lymphatic vessel with characteristic bicuspid valve. SC = sclera.</p>
Full article ">Figure 4
<p>Box-and-whisker plot showing IOP change after surgery. The colored boxes represent the 25th and 75th percentile, the solid horizontal lines in the colored boxes represent the median, X represents the mean, vertical solid black lines extend the interquartile range 1.5 times, and the colored dots represent outliers.</p>
Full article ">Figure 5
<p>Bar diagram showing mean hypotensive medication use after surgery at different follow-up times.</p>
Full article ">Figure 6
<p>The Kaplan–Meier survival curve after surgery.</p>
Full article ">Figure 7
<p>Showing different patterns of lymphatic vessels. (<b>a</b>,<b>b</b>,<b>d</b>,<b>e</b>) Lymphatics in the form of plexus. (<b>c</b>) Radially running vessels. (<b>f</b>) A case with few vessels.</p>
Full article ">Figure 8
<p>Development of lymphatic vessels immediately after the Nd:YAG laser trabeculotomy. (<b>a</b>) Showing conjunctiva medial to the surgery site immediately after trabeculotomy. Some irregular shaped swellings started appearing in the conjunctiva as aqueous humor began its exit from the anterior chamber. (<b>b</b>) Slit lamp view 15 min after trabeculotomy showing appearance of a plexus of LV. (<b>c</b>) Clinical image taken after a period of two weeks. The LV plexus is reduced in size and the IOP is below ten. (<b>d</b>) An OCT scan of the same area showing the presence of LV 1 week after the trabeculotomy. BLV = bicuspid lymphatic valves, LV = lymphatic vessels.</p>
Full article ">Figure 9
<p>Conjunctival lymphatic plexus in the right eye of a male patient having undergone a combined procedure. An Nd:YAG laser trabeculotomy was performed seven days after surgery. (<b>a</b>,<b>b</b>) Clinical image of surgery site 2 weeks after trabeculotomy. Lymphatic vessels are filled with transparent fluid (black arrows). (<b>c</b>) After 3 months, the patient had an increase in IOP due to blockage of the trabeculotomy site by iris tissue (black arrow). A repeat trabeculotomy near to the blockage site lowered IOP below the target level and it remained this way for the rest of the follow-up period. (<b>d</b>) Image of the surgery site taken 4 months after the trabeculotomy showing absence of any bleb. (<b>e</b>–<b>g</b>) OCT scans identifying the lymphatic nature of vessels in the conjunctiva lying over the scleral flap and in the conjunctiva adjacent to the medial and lateral borders of the surgery site (white arrows). BLV = bicuspid lymphatic valves, IOP = intraocular pressure, LV = lymphatic vessels, OCT = optical coherence tomography.</p>
Full article ">Figure 10
<p>The proposed mechanism of aqueous humor outflow after the proposed glaucoma surgery.</p>
Full article ">
Back to TopTop